Ipsen Biopharmaceuticals Inc announces that the US Food and Drug Administration has expanded its approval for the use of Dysport (abobotulinumtoxinA) via injection for the treatment of lower limb spasticity in adults. In July 2015, Dysport was approved for the treatment of upper limb spasticity in adults. In July 2016,…
Source: RM
Read more: FDA Approves Dysport for the Treatment of Lower Limb Spasticity in Adults